Back
Full-text
Journal article

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

  • Scarfò L Università Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy.
  • Chatzikonstantinou T Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
  • Rigolin GM Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Quaresmini G USC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy.
  • Motta M S.C. Ematologia, ASST Spedali Civili, Brescia, Italy.
  • Vitale C University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
  • Garcia-Marco JA Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
  • Hernández-Rivas JÁ Hospital Universitario Infanta Leonor, Madrid Universidad Complutense, Madrid, Spain.
  • Mirás F Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Baile M Servicio de Hematología del Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain.
  • Marquet J Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Niemann CU Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Reda G U.O.C. Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Munir T St James's University Hospital, Leeds, UK.
  • Gimeno E Hematology Department Hospital del Mar, Barcelona, Spain.
  • Marchetti M Hematology Dpt, Az Osp SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Quaglia FM Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Varettoni M Division of Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Delgado J Dept. of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain.
  • Iyengar S Department of Haemato-Oncology, Royal Marsden Hospital, London, UK.
  • Janssens A Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
  • Marasca R Hematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Ferrari A Hematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Cuéllar-García C Hematology Unit, Consorci Sanitari Terrassa Hospital, Terrassa, Spain.
  • Itchaki G Rabin Medical Center, Beilinson Hospital; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Špaček M 1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
  • De Paoli L Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Laurenti L Dipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Roma, Italy.
  • Levin MD Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Lista E Struttura Semplice Dipartimentale di Ematologia, Presidio Ospedaliero Santa Chiara, Trento, Italy.
  • Mauro FR Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.
  • Šimkovič M Department of Internal Medicine-Haematology, University Hospital and Medical School Hradec Kralove, Hradec Kralove, Czech Republic.
  • Van Der Spek E Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
  • Vandenberghe E Department of Haematology, St James Hospital and Trinity College Dublin, Dublin, Ireland.
  • Trentin L Hematology Unit, University of Padua, Padua, Italy.
  • Wasik-Szczepanek E Dept. Hematooncology and Bone Marrow Transplantation, Medical University in Lublin, Lublin, Poland.
  • Ruchlemer R Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Bron D Inst J Bordet (ULB), Brussels, Belgium.
  • De Paolis MR UOC Ematologia PO Vito Fazzi Lecce, Lecce, Italy.
  • Del Poeta G Cattedra di Ematologia Dipartimento di Biomedicina e Prevenzione, Università Tor Vergata Roma, Rome, Italy.
  • Farina L Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Foglietta M SC Ematologia, AO S. Croce e Carle, Cuneo, Italy.
  • Gentile M UOC Ematologia AO Cosenza, Cosenza, Italy.
  • Herishanu Y Department of Hematology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
  • Herold T Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Jaksic O Department of Hematology, University hospital Dubrava, Zagreb, Croatia.
  • Kater AP Dep of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Kersting S Department of Hematology, Haga Hospital, The Hague, The Netherlands.
  • Malerba L Hematology Unit, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", Pesaro, Italy.
  • Orsucci L Division of Hematology II, San Giovanni Battista Hospital, Torino, Italy.
  • Popov VM Colentina Clinical Hospital Bucharest, Bucharest, Romania.
  • Sportoletti P Institute of Hematology and Center for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
  • Yassin M National Center for Cancer Care and Research Doha, Doha, Qatar.
  • Pocali B Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy.
  • Barna G 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
  • Chiarenza A Division of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
  • Dos Santos G Hospital de Clinicas, Montevideo, Uruguay.
  • Nikitin E Department of Hematology, Oncology, and Chemotherapy, S. P. Botkin's City Hospital, Moscow, Russia.
  • Andres M Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Dimou M 1st First Propedeutic Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens, Medical School of Athens, Athens, Greece.
  • Doubek M University Hospital and CEITEC MU Brno, Brno, Czech Republic.
  • Enrico A Hematology Area, Hospital Italiano La Plata, La Plata, Argentina.
  • Hakobyan Y Hematology Center after Prof. Yeolyan MH RA, Yerevan, Armenia.
  • Kalashnikova O First State Pavlov Medical University of Saint-Petersburg, Raisa Gorbacheva Memorial Institute for Children Oncology, Hematology and Transplantation Russia, Saint-Petersburg, Russia.
  • Ortiz Pareja M Carlos Haya, Málaga, Spain.
  • Papaioannou M Hematology Unit, 1st Dept of Internal Medicine, AUTH, AHEPA Hospital, Thessaloniki, Greece.
  • Rossi D Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Shah N Norfolk & Norwich University NHS Foundation Trust, Norwich, UK.
  • Shrestha A Hematology Unit, Nepal Cancer Hospital & Research Centre, Lalitpur, Nepal.
  • Stanca O "Carol Davila" University of Medicine and Pharmacy, Hematology Clinic, Coltea Clinical Hospital, Bucharest, Romania.
  • Stavroyianni N Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
  • Strugov V Hematology Almazov National Medical Research Centre, St. Petersburg, Russia.
  • Tam C Peter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia.
  • Zdrenghea M Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy and Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania.
  • Coscia M University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
  • Stamatopoulos K Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. kostas.stamatopoulos@certh.gr.
  • Rossi G S.C. Ematologia, ASST Spedali Civili, Brescia, Italy.
  • Rambaldi A USC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy.
  • Montserrat E Dept. of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain.
  • Foà R Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.
  • Cuneo A Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Ghia P Università Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy. ghia.paolo@hsr.it.
Show more…
  • 2020-07-11
Published in:
  • Leukemia. - 2020
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents
Betacoronavirus
Comorbidity
Coronavirus Infections
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Pandemics
Pneumonia, Viral
Prognosis
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Retrospective Studies
Severity of Illness Index
Surveys and Questionnaires
English Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/111354
Statistics
Document views: 9 File downloads:
  • fulltext.pdf: 0